| abstract |
The present invention provides a new human bladder cancer tumor marker - abnormally glycosylated integrin AG-α3β1, hybridoma cells producing monoclonal antibody against the tumor marker, and the secreted monoclonal antibody BCMab1, the epitope recognized by the BCMab1 antibody is [3OSO3]Galb1-4(Fuca1-3)[6OSO3]GlcNAc. The monoclonal antibody has a strong positive reaction with human bladder cancer cell line T24 and human bladder cancer tissue, but has no cross-reaction with human normal bladder tissue and other non-bladder cancer cells. At the same time, the monoclonal antibody has the function of inhibiting the proliferation of bladder cancer cell line T24 in in vitro cell culture and animal tumor models. The invention also provides an in vitro diagnostic kit comprising the monoclonal antibody BCMab1 and a method for detecting the content of tumor markers in urine exfoliated cells by using the monoclonal antibody BCMab1. |